Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Journal of Medicinal Chemistry

Volumn 59, Issue 15, 2016, Pages 7268-7274

  Zhang, Ji Quan ^a,b   Luo, Yong Jie ^a   Xiong, Yan Shi ^a   Yu, Yang ^a   Tu, Zheng Chao ^c   Long, Zi Jie ^a   Lai, Xiao Ju ^d   Chen, Hui Xuan ^a   Luo, Yu ^a   Weng, Jiang ^a   Lu, Gui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

AMINATION; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYCLIZATION; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IN VITRO STUDY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84982152984     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00235     Document Type: Article

References (23)

1. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer Nat. Rev. Cancer 2002, 2, 489-501 10.1038/nrc839
2. Smith, A. L.; D'Angelo, N. D.; Bo, Y. Y.; Booker, S. K.; Cee, V. J.; Herberich, B.; Hong, F.-T.; Jackson, C. L. M.; Lanman, B. A.; Liu, L.; Nishimura, N.; Pettus, L. H.; Reed, A. B.; Tadesse, S.; Tamayo, N. A.; Wurz, R. P.; Yang, K.; Andrews, K. L.; Whittington, D. A.; McCarter, J. D.; Miguel, T. S.; Zalameda, L.; Jiang, J.; Subramanian, R.; Mullady, E. L.; Caenepeel, S.; Freeman, D. J.; Wang, L.; Zhang, N.; Wu, T.; Hughes, P. E.; Norman, M. H. Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases J. Med. Chem. 2012, 55, 5188-5219 10.1021/jm300184s
3. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat. Rev. Genet. 2006, 7, 606-619 10.1038/nrg1879
4. Vanhaesebroeck, B.; Leevers, S. J.; Ahmadi, K.; Timms, J.; Katso, R.; Driscoll, P. C.; Woscholski, R.; Parker, P. J.; Waterfield, M. D. Synthesis and function of 3-phosphorylated insitol lipids Annu. Rev. Biochem. 2001, 70, 535-602 10.1146/annurev.biochem.70.1.535
5. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer Nat. Rev. Drug Discovery 2009, 8, 627-644 10.1038/nrd2926
6. Hollander, M. C.; Blumenthal, G. M.; Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models Nat. Rev. Cancer 2011, 11, 289-301 10.1038/nrc3037
7. Burger, M. T.; Pecchi, S.; Wagman, A.; Ni, Z.-J.; Knapp, M.; Hendrickson, T.; Atallah, G.; Pfister, K.; Zhang, Y.; Bartulis, S.; Frazier, K.; Ng, S.; Smith, A.; Verhagen, J.; Haznedar, J.; Huh, K.; Iwanowicz, E.; Xin, X.; Menezes, D.; Merritt, H.; Lee, I.; Wiesmann, M.; Kaufman, S.; Crawford, K.; Chin, M.; Bussiere, D.; Shoemaker, K.; Zaror, I.; Maira, S.-M.; Voliva, C. F. Identification of NVP-BKM120 as a potent, pelective, orally bioavailable class I PI3 kinase inhibitor for treating cancer ACS Med. Chem. Lett. 2011, 2, 774-779 10.1021/ml200156t
8. Burger, M. T.; Knapp, M.; Wagman, A.; Ni, Z.-J.; Hendrickson, T.; Atallah, G.; Zhang, Y.; Frazier, K.; Verhagen, J.; Pfister, K.; Ng, S.; Smith, A.; Bartulis, S.; Merrit, H.; Weismann, M.; Xin, X.; Haznedar, J.; Voliva, C. F.; Iwanowicz, E.; Pecchi, S. Synthesis and in vitro and in vivo evaluation of phosphoinositide-3-kinase inhibitors ACS Med. Chem. Lett. 2011, 2, 34-38 10.1021/ml1001932
9. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine Mol. Cell 2000, 6, 909-919 10.1016/S1097-2765(05)00089-4
10. Knight, Z. A.; Chiang, G. G.; Alaimo, P. J.; Kenski, D. M.; Ho, C. B.; Coan, K.; Abraham, R. T.; Shokat, K. M. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold Bioorg. Med. Chem. 2004, 12, 4749-4759 10.1016/j.bmc.2004.06.022
11. Stemke-Hale, K.; Gonzalez-Angulo, A. M.; Lluch, A.; Neve, R. M.; Kuo, W.-L.; Davies, M.; Carey, M.; Hu, Z.; Guan, Y.; Sahin, A.; Symmans, W. F.; Pusztai, L.; Nolden, L. K.; Horlings, H.; Berns, K.; Hung, M.-C.; van de Vijver, M. J.; Valero, V.; Gray, J. W.; Bernards, R.; Mills, G. B.; Hennessy, B. T. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer Cancer Res. 2008, 68, 6084-6091 10.1158/0008-5472.CAN-07-6854
12. Thomas, R. K.; Baker, A. C.; DeBiasi, R. M.; Winckler, W.; LaFramboise, T.; Lin, W. M.; Wang, M.; Feng, W.; Zander, T.; MacConnaill, L. E.; Lee, J. C.; Nicoletti, R.; Hatton, C.; Goyette, M.; Girard, L.; Majmudar, K.; Ziaugra, L.; Wong, K.-K.; Gabriel, S.; Beroukhim, R.; Peyton, M.; Barretina, J.; Dutt, A.; Emery, C.; Greulich, H.; Shah, K.; Sasaki, H.; Gazdar, A.; Minna, J.; Armstrong, S. A.; Mellinghoff, I. K.; Hodi, F. S.; Dranoff, G.; Mischel, P. S.; Cloughesy, T. F.; Nelson, S. F.; Liau, L. M.; Mertz, K.; Rubin, M. A.; Moch, H.; Loda, M.; Catalona, W.; Fletcher, J.; Signoretti, S.; Kaye, F.; Anderson, K. C.; Demetri, G. D.; Dummer, R.; Wagner, S.; Herlyn, M.; Sellers, W. R.; Meyerson, M.; Garraway, L. A. High-throughput oncogene mutation profiling in human cancer Nat. Genet. 2007, 39, 347-351 10.1038/ng1975
13. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K. V.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers Science 2004, 304, 554 10.1126/science.1096502
14. Kim, K. J.; Wang, L.; Su, Y.-C.; Gillespie, G. Y.; Salhotra, A.; Lal, B.; Laterra, J. Systemic anti-hepatocyte growth factormonoclonal antibody therapy induces the regression of intracranial glioma xenografts Clin. Cancer Res. 2006, 12, 1292-1298 10.1158/1078-0432.CCR-05-1793
15. Jiang, W.; Jin, G.; Ma, D.; Wang, F.; Fu, T.; Chen, X.; Chen, X.; Jia, K.; Marikar, F. M. M. T.; Hua, Z. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth PLoS One 2012, 7, e37132 10.1371/journal.pone.0037132
16. Zheng, F.-M.; Long, Z.-J.; Hou, Z.-J.; Luo, Y.; Xu, L.-Z.; Xia, J.-L.; Lai, X.-J.; Liu, J.-W.; Wang, X.; Kamran, M.; Yan, M.; Shao, S.-J.; Lam, E. W.-F.; Wang, S.-W.; Lu, G.; Liu, Q. A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance Mol. Cancer Ther. 2014, 13, 1991-2003 10.1158/1535-7163.MCT-13-1029
17. Nacht, M.; Qiao, L.; Sheets, M. P.; St. Martin, T.; Labenski, M.; Mazdiyasni, H.; Karp, R.; Zhu, Z.; Chaturvedi, P.; Bhavsar, D.; Niu, D.; Westlin, W.; Petter, R. C.; Medikonda, A. P.; Singh, J. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα J. Med. Chem. 2013, 56, 712-721 10.1021/jm3008745
18. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 2003, 24, 1999-2012 10.1002/jcc.10349
19. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174 10.1002/jcc.20035
20. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model J. Phys. Chem. 1993, 97, 10269-10280 10.1021/j100142a004
21. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath J. Chem. Phys. 1984, 81, 3684-3690 10.1063/1.448118
22. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935 10.1063/1.445869
23. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes J. Comput. Phys. 1977, 23, 327-341 10.1016/0021-9991(77)90098-5